Adipotide is a weight loss peptide with impressive preclinical results in fat reduction but poses serious risks of kidney toxicity, leading to its clinical development being halted. It's not FDA-approved and is dangerous for human use due to the absence of a safe therapeutic window.
Mechanism
Adipotide targets the blood vessels supplying white adipose tissue, triggering fat cell death through a unique dual-domain approach: a homing peptide that binds to prohibitin receptors on endothelial cells and a pro-apoptotic domain that disrupts mitochondrial integrity, resulting in targeted fat loss. However, this mechanism also inflicts significant kidney damage, as all treated subjects experienced renal toxicity.
Research
In primate studies, Adipotide led to significant weight loss--up to 11% within 28 days--and improved insulin sensitivity. However, human trials were abruptly halted due to serious nephrotoxic effects, with all participants suffering kidney damage, leading to the compound's abandonment in 2019. No efficacy data from human trials are available beyond initial dosing assessments.
Synergies
Given Adipotide's severe renal risks, exploring safer weight management alternatives is crucial. Ben IQ evaluates YOUR lab results and goals to identify the best stacking strategies.
Trade-Offs
While Adipotide shows potential for fat loss, its extreme nephrotoxicity raises critical safety concerns that far outweigh the benefits. Always consider YOUR unique data and situation.